MedTrace Logo

Efficacy and Safety of Curcumin Formulation in Alzheimer's Disease

NCT01001637 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2023-09-28

No results posted yet for this study

Summary

Curcumin is shown to impact several different pathways of neuroprotection, however clinical trials have not shown positive results, due to the poor bioavailability of curcumin. This study is designed to determine efficacy and safety of high-bioavailability curcumin formulation (Longvida) in subjects with Alzheimer's disease.

Conditions

  • Alzheimer Disease

Interventions

DIETARY_SUPPLEMENT

Curcumin Formulation

2000mg or 3000mg daily BID

DIETARY_SUPPLEMENT

Placebo

Placebo

Sponsors & Collaborators

  • Pharmanza Herbal Pvt Ltd

    collaborator UNKNOWN

  • Verdure Sciences

    collaborator INDUSTRY

  • University of California, Los Angeles

    collaborator OTHER

  • Jaslok Hospital and Research Centre

    lead OTHER

Principal Investigators

  • Fali Poncha, DM neuro · Jaslok Hospital and Research Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-06-30
Completion
2010-11-30

Countries

  • India

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01001637 on ClinicalTrials.gov